Showing 1 - 11 results of 11 for search 'S. S. Tykodi', query time: 0.03s Refine Results
  1. 1
    A taste of science : an anthology of writings by scientists, writings of good literary quality showing - among other things - the human side of science/

    A taste of science : an anthology of writings by scientists, writings of good literary quality showing - among other things - the human side of science/ by Tykodi, Ralph John

    Published 1975
  2. 2
    Editorial: Immune checkpoint inhibitors in renal cell carcinoma

    Editorial: Immune checkpoint inhibitors in renal cell carcinoma by Scott S. Tykodi, Renate Pichler

    Published 2023-04-01
    Get full text
    Article
  3. 3
    Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

    Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma by Yuexin Xu, Chris P. Miller, Edus H. Warren, Scott S. Tykodi

    Published 2021-07-01
    Get full text
    Article
  4. 4
    Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes

    Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded cl... by Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Shreeram Akilesh, Chris P. Miller, Chris P. Miller, Scott S. Tykodi, Scott S. Tykodi, Edus H. Warren, Edus H. Warren, Edus H. Warren

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

    Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system by Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodi

    Published 2023-12-01
    Get full text
    Article
  6. 6
    610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell carcinoma

    610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell... by Shailender Bhatia, Ramesh Rengan, Sylvia M Lee, Scott S Tykodi, Jing Zeng, Mary Redman, Peter H Goff, Kelsey K Baker

    Published 2023-11-01
    Article
  7. 7
    Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

    Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma by Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin

    Published 2022-08-01
    Get full text
    Article
  8. 8
    Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

    Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma by Chung-Wei Lee, Thomas Powles, Sabina Signoretti, David F McDermott, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang

    Published 2022-12-01
    Get full text
    Article
  9. 9
    Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

    Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p... by Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson

    Published 2022-09-01
    Get full text
    Article
  10. 10
    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

    Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition by Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott

    Published 2019-02-01
    Get full text
    Article
  11. 11
    Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

    Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry by M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman, N. Gregory, D. F. McDermott

    Published 2019-03-01
    Get full text
    Article

Search Tools: